Symbols

BFRI

Biofrontera·NASDAQ

--(--)

BFRI fundamentals

BFRI Q4 2025 Earnings

Biofrontera (BFRI) released its earnings on Mar 19, 2026: revenue was 17.10M (YoY +36.15%), beat estimates; EPS was 0.195 (YoY +202.63%), met estimates.

Revenue / YoY

17.10M

+36.15%

EPS / YoY

0.195

+202.63%

Report date

Mar 19, 2026

BFRI Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 36% YoY to $17.1M, FY2025 up 12% to $41.7M.
Gross Margin Transformation: Q4 2025 gross profit 82% vs. 58% prior, targeting 80-85% in 2026.
Clinical Breakthroughs:
- sBCC sNDA with 76% histological clearance, PDUFA date Sept 28, 2026.
- AK extremities Phase III success, acne Phase IIb 58% lesion reduction.
Financial Health: Q4 net income $5.6M, FY2025 cash position $6.4M, on track for 2026 cash flow breakeven.

Earnings

EPS

Revenue

Revenue & Expenses

BFRI has released its 2025 Q4 earnings report, with revenue of 17.10M, reflecting a YoY change of 36.16%, and net profit of 5.64M, showing a YoY change of 504.01%. The Sankey diagram below clearly presents BFRI's revenue sources and cost distribution.

Key Indicators

Biofrontera (BFRI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biofrontera (BFRI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Biofrontera (BFRI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Biofrontera (BFRI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown